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The fragile X mental retardation protein (FMRP) is an
RNA-binding protein that controls translational
efficiency and regulates synaptic plasticity. Here,
we report that FMRP is involved in dopamine (DA)
modulation of synaptic potentiation. AMPA gluta-
mate receptor subtype 1 (GluR1) surface expression
and phosphorylation in response to D1 receptor
stimulation were reduced in cultured Fmr1/
prefrontal cortex (PFC) neurons. Furthermore, D1 re-
ceptor signaling was impaired, accompanied by D1
receptor hyperphosphorylation at serine sites and
subcellular redistribution of G protein-coupled re-
ceptor kinase 2 (GRK2) in both PFC and striatum of
Fmr1/ mice. FMRP interacted with GRK2, and
pharmacological inhibition of GRK2 rescued D1
receptor signaling in Fmr1/ neurons. Finally, D1 re-
ceptor agonist partially rescued hyperactivity and
enhanced the motor function of Fmr1/ mice. Our
study has identified FMRP as a key messenger for
DA modulation in the forebrain and may provide
insights into the cellular and molecular mechanisms
underlying fragile X syndrome.
INTRODUCTION
Dopamine (DA) in the prefrontal cortex (PFC) plays a critical role
in cognitive functions and neuropsychiatric pathology (Huang
et al., 2004; Seamans and Yang, 2004; Surmeier, 2007). The
DA input to PFC from the ventral tegmental area (VTA) regulates
many aspects of working memory, planning, and attention, and
its dysfunctions are suggested to contribute to neuropsychiatric
disorders (Carlsson, 2001; Castner et al., 2000; Seamans and
Yang, 2004). DA functions in its target cells through five subtypes
of DA receptors (D1–D5) (Huang and Kandel, 1995; West and
Grace, 2002; Williams and Goldman-Rakic, 1995). Understand-
ing the signaling pathways of DA receptor-mediated modulation
may provide new insights into the cellular mechanisms underly-
ing various DA-associated mental disorders.634 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.Fragile X syndrome is a common inherited mental retardation
caused by the lack of fragile X mental retardation protein (FMRP)
due to silencing of the FMR1 gene (Feng et al., 1995; Garber
et al., 2006). It has been proposed that FMRP may act as a local
regulator for synaptic plasticity (Bagni and Greenough, 2005;
Garber et al., 2006; Grossman et al., 2006). Previously, we
showed that FMRP is critical for NMDA receptor-dependent
long-term potentiation (LTP) in the cingulate region of the PFC
in trace fear memory (Zhao et al., 2005a). Deficits in activity-de-
pendent synaptic plasticity have also been observed in piri-
form cortices and the hippocampal CA1 region of Fmr1/ mice
(Larson et al., 2005; Lauterborn et al., 2007). Fragile X syndrome
is often accompanied by neuropsychiatric disorders such as
hyperactivity, attention disorders, and autism (Bagni and Green-
ough, 2005; Bear et al., 2004; Grossman et al., 2006), suggesting
that the lack of FMRP may affect DA function. However, no link
between FMRP and DA modulation has been studied thus far.
Here, we employed integrative approaches to demonstrate
that FMRP contributes to DA modulation of AMPA glutamate
receptor subtype 1 (GluR1) receptor synaptic insertion and
dopaminergic facilitation of LTP. We found that the surface ex-
pression and phosphorylation of AMPA GluR1 receptors at the
cAMP-dependent protein kinase (PKA) phosphorylation site in-
duced by stimulating D1 receptors was attenuated in Fmr1/
PFC neurons. DA-mediated facilitation of LTP was absent in cin-
gulate region of PFC slices of adult Fmr1/ mice. The hyper-
phosphorylation of the D1 receptor at serine sites and the in-
crease of G protein-coupled receptor kinase 2 (GRK2) in the
cell membrane contribute to the impairment of D1 receptor sig-
naling in both PFC and striatum of Fmr1/ mice. FMRP interacts
with GRK2, and pharmacological inhibition of GRK2 rescued D1
receptor signaling in Fmr1/ neurons. DA D1 receptor agonist
partially rescued hyperactivity and enhanced the motor function
of Fmr1/ mice. These findings provide direct evidence that
FMRP acts as a key messenger for DA receptor-mediated
modulation in forebrain neurons.
RESULTS
Activation of DA D1 or D2 Receptors
in Cultured Cortical Neurons
DA transmission is mediated by five G protein-coupled receptors
(GPCRs) classified as either D1-type (D1 and D5 subtypes) or
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FMRP and Dopamine Modulation in ForebrainFigure 1. The Effect of Dopamine Receptor Activation on AMPA
Receptor GluR1 Subunits in Cultured Prefrontal Cortical Neurons
Surface biotinylation assays following treatment of cultured prefrontal cortical
(PFC) neurons with D1 agonists (SKF81297 and dihydrexidine) or D2 agonists
(quinpirole and bromocriptine) for 10 min at a concentration of 5 mM. n = 4
dishes per group; *p < 0.01 versus control. Data are normalized to the control
values and are expressed as mean ± SEM.
(A) GluR1 surface expression was increased after D1 agonist treatment,
whereas it was decreased by D2 agonists.
(B) The D1 antagonist SCH23390 (5 mM) blocked the increase in GluR1 surface
expression following D1 agonist treatment.
(C) Dose-dependent effect of the D1 agonist SKF81297 on GluR1 surface
expression. The highest level of GluR1 surface expression was seen from
5 mM.D2-type (D2–D4 subtypes) (Missale et al., 1998; Seamans and
Yang, 2004). In cultured rat cortical neurons, DA D1 receptors
are positively coupled to the PKA signaling pathway through
Gs proteins and contribute to AMPA GluR1 receptor trafficking
(Sun et al., 2005). To determine whether DA also affects AMPA
receptor functions in mouse PFC neurons, we treated cultured
PFC neurons with the D1 receptor agonists SKF81297 and dihy-
drexidine or the D2 receptor agonists quinpirole and bromocrip-
tine. Neither D1 nor D2 receptor agonists affected the total
expression levels of GluR1 or GluR2/3 in cultures (see Figures
S1A and S1B available online). Surface expression of GluR1
was increased after treatment with D1 receptor agonists but
was decreased by D2 receptor agonists (p < 0.01 versus control,
n = 4 dishes; Figure 1A). Surface expression of GluR2 and 3 was
unchanged (Figure S1C). The effect of D1 receptor agonists
on GluR1 surface expression was blocked by the D1 receptor
antagonist SCH23390 (Figure 1B). The D1 receptor agonist
SKF81297 increased GluR1 surface expression in a dose-de-
pendent manner (Figure 1C). These findings demonstrate that
D1 receptor activation can facilitate the surface expression of
AMPA GluR1 receptors.
The phosphorylation of the AMPA receptor GluR1 subunit
plays a key role in its synaptic expression and synaptic plasticity
(Esteban et al., 2003; Snyder et al., 2000). We studied the phos-
phorylation of GluR1 by DA receptor activation at two sites: the
PKA phosphorylation site at Ser845, and the PKC or calcium/cal-
modulin-dependent protein kinase II (CaMKII) phosphorylation
site at Ser831 (Man et al., 2007; Snyder et al., 2000). We
compared the effect of D1 or D2 receptor agonists on the phos-
phorylation of GluR1 in cultured neurons and found that the
phosphorylation of GluR1 at Ser845 was increased by D1 recep-
tor agonists and decreased by D2 receptor agonists (p < 0.01
versus control, n = 4 dishes; Figure 1D). In contrast, the phos-
phorylation level of GluR1 at Ser831 was not affected by either
D1 or D2 receptor agonists (Figure 1E). The effect of D1 receptor
agonists on the phosphorylation of GluR1 was blocked by the D1
receptor antagonist SCH23390 (Figure 1F), further supporting
the idea that D1 receptor activation can induce phosphorylation
of AMPA GluR1 at Ser845.
Requirement of FMRP for D1 Receptor
Agonist-Produced Effects
To investigate the role of FMRP in DA receptor signaling, we
tested the effects of the D1 agonist SKF81297 on GluR1 in cul-
tured PFC neurons of Fmr1/ mice. We found that the surface
expression of GluR1 triggered by SKF81297 in Fmr1/ PFC
neurons was impaired compared to that of wild-type (WT) mice
(WT, 2.25 ± 0.08; Fmr1/, 1.42 ± 0.05; p < 0.05, n = 6 dishes;
Figure 2A). SKF81297 did not affect the total expression of
GluR1 and GluR2/3 receptors in WT or Fmr1/ neurons (Figures
S2A and S2B). However, no difference in the total expression
levels of GluR1 and GluR2/3 receptors was found between WT
(D) GluR1 phosphorylation at Ser845 was increased by D1 agonist treatment
but decreased by D2 agonists.
(E) GluR1 phosphorylation at Ser831 was unchanged.
(F) The D1 antagonist SCH23390 (5 mM) blocked increased GluR1 phosphor-
ylation at Ser845 induced by D1 agonists.Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 635
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S2B). Furthermore, there was no change in the surface expres-
sion of GluR1 and GluR2/3 receptors between WT and Fmr1/
neurons under basal conditions (Figure 2A; Figure S2C). These
results provide direct evidence that FMRP is involved in DA
receptor signaling and contributes to GluR1 surface expression
induced by D1 receptor activation.
We next compared the D1 receptor agonist-triggered phos-
phorylation of GluR1 in WT and Fmr1/ neurons. While there
was no difference in the basal phosphorylation of GluR1 at
both Ser845 and Ser831 (Figures 2B and 2C), the increased
phosphorylation of GluR1 receptors at Ser845 induced by D1
Figure 2. GluR1 Surface Expression and Phosphorylation after D1
Receptor Activation in Cultured PFC Neurons of Fmr1/ Mice
Cultures were treated with SKF81297 (5 mM) for 10 min. Data are normalized to
wild-type (WT) control values and are expressed as mean ± SEM.
(A) The increase in GluR1 surface expression levels was attenuated in Fmr1/
neurons compared to WT. *p < 0.05, **p < 0.01 versus control; #p < 0.05 versus
WT; n = 6 dishes.
(B) There was no difference in the basal phosphorylation levels of GluR1 at
Ser845 between Fmr1/ and WT neurons. The increase in GluR1 phosphor-
ylation at Ser845 was attenuated in Fmr1/ neurons. *p < 0.05, **p < 0.01
versus control; #p < 0.05 versus WT; n = 6 dishes.
(C) There was no difference in GluR1 phosphorylation at Ser831 between
Fmr1/ and WT neurons. GluR1 phosphorylation at Ser831 remained
unchanged after SKF81297 treatment (n = 6 dishes).
(D) There was no difference in D1 receptor levels between Fmr1/ and WT
neurons (n = 6 dishes).636 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.activation was almost abolished in Fmr1/ neurons (WT, 2.33 ±
0.09; Fmr1/, 1.40 ± 0.05; p < 0.05, n = 6 dishes; Figure 2B).
The effect of FMRP deletion was relatively selective. SKF81297
did not affect the phosphorylation of GluR1 at Ser831 in
Fmr1/ neurons (Figure 2C). We also found that the expression
levels of D1 receptors in cultured PFC neurons of Fmr1/ mice
were similar to that of WT mice (Figure 2D).
Decreased Synaptic GluR1 Delivery in Fmr1/ Mice
The homomeric GluR1 AMPA receptor has a faster decay time
than heteromeric GluR2 AMPA receptors (Thiagarajan et al.,
2005). During electrophysiological recordings in cultured neu-
rons, bath application of SKF81297 caused a significant decrease
in the decay time of AMPA miniature excitatory postsynaptic
currents (mEPSCs) (2.56 ± 0.31 ms, n = 12 cells; p < 0.05
versus control, 3.15 ± 0.15 ms, n = 12 cells) in WT PFC neurons,
whereas the decay time was unchanged in Fmr1/ mice (Fig-
ures S3A–S3C). These data provide functional evidence that
synaptic GluR1 trafficking is altered by D1 receptor activation
and that FMRP is required for DA-triggered GluR1 insertion.
FMRP can be rapidly translated in an activity-dependent man-
ner (Hou et al., 2006; Weiler et al., 2004). PSD-95, a key scaffold-
ing protein involved in synaptic plasticity, modulates DA-medi-
ated phosphorylation of AMPA receptors (Swayze et al., 2004).
FMRP contributes to group I metabotropic glutamate receptor-
dependent translation of PSD-95 (Todd et al., 2003). We found
that neither FMRP nor PSD-95 expression levels were altered
in cultured PFC neurons following D1 receptor activation (Fig-
ures S3D and S3E), indicating that D1 receptor activation does
not affect FMRP or PSD-95 expression.
Impaired Facilitation of Synaptic LTP by D1 Receptors
in Fmr1/ Mice
The PFC, including its cingulate region, plays an important role in
learning and memory, drug addiction, and pain (Courtney et al.,
1998; Rainville et al., 1997; Zhao et al., 2005a; Zhuo, 2002). To
further test the effect of D1 receptor activation on synaptic plas-
ticity, we performed whole-cell patch-clamp recordings in visu-
ally identified pyramidal neurons in the cingulate region of PFC
slices from adult WT mice. Bath application of the D1 receptor
agonist SKF81297 had no effect on basal synaptic transmission
(105.7% ± 7.0%, n = 9 cells; Figure 3A). We next paired D1 ag-
onist application with an LTP induction protocol and found that
bath application of SKF81297 for 10 min paired with the LTP in-
duction protocol significantly enhanced the amplitude of LTP
(176.4% ± 11.3%, n = 9 cells; p < 0.05 versus pairing training
only; Figures 3B and 3C), suggesting that D1 receptor activation
can facilitate LTP induction. However, the enhancing effect of
SKF81297 was abolished in Fmr1/ mice (114.1% ± 5.8%,
n = 13 cells; p > 0.05 versus baseline responses; Figures 3B
and 3C), demonstrating that dopaminergic facilitation of LTP
is impaired in Fmr1/ mice and that FMRP is required for
dopaminergic facilitation of LTP.
Both presynaptic and postsynaptic mechanisms contribute to
LTP expression (Kandel, 2001; Malinow and Malenka, 2002; Nic-
oll and Malenka, 1995; Song and Huganir, 2002). To determine
whether presynaptic and/or postsynaptic mechanisms are
involved in dopaminergic modulation of LTP, we measured
Neuron
FMRP and Dopamine Modulation in ForebrainFigure 3. Dopaminergic Facilitation of
Long-Term Potentiation Is Impaired in the
Anterior Cingulate Cortex of Fmr1/ Mice
(A) The D1 agonist SKF81297 (5 mM) had no effect
on basal synaptic transmission (n = 9 cells).
(B) SKF81297 paired with training facilitated
long-term potentiation (LTP) induction in WT mice
(, n = 9); SKF81297 failed to facilitate LTP induc-
tion in Fmr1/ mice (B, n = 13 cells). Insets show
averages of six excitatory postsynaptic currents
(EPSCs) at the time points of 5 (pre) and 35
(post) min during the recording.
(C) Summary of the effects of SKF81297 (5 mM, 10
min) on LTP induction in WT and Fmr1/ mice.
*p < 0.05 versus baseline; #p < 0.05 versus pairing
training.
(D) Pep1-TGL (100 mM) blocked LTP expression in
the presence of SKF81297 (n = 5 cells).
(E) SKF81297 (5 mM, 20 min) had no effect on
NMDA EPSCs (n = 5 cells). The dashed line indi-
cates the mean basal synaptic responses.
(F) There was no difference in D1 receptor levels in
PFC slices between Fmr1/ and WT mice as
shown by western blot (n = 6 mice). Data are nor-
malized to WT values.
(G) The affinity of the D1 receptor agonist
SKF38393 for [3H]SCH23390 binding sites was
measured in PFC. The affinity of SKF38393 was
not changed in PFC of Fmr1/ mice (42% ±
11% and 56% ± 15% for WT and Fmr1/ mice,
respectively; n = 3 measurements, p > 0.05 versus
WT; PFC tissues from six mice were used for each
measurement).
Data are expressed as mean ± SEM.paired-pulse facilitation (PPF) before and after perfusion of
the D1 receptor agonist SKF81297 and LTP induction. The PPF
(50 ms interval) was not altered (Figures S4A–S4C), suggesting
that facilitation of LTP by D1 receptor activation in PFC likely
depends on postsynaptic mechanisms. To confirm the role of
GluR1 receptors in the facilitation of LTP by D1 receptor activa-
tion, we tested the effects of the GluR1 C-terminal peptide ana-
log Pep1-TGL, which has been shown to interfere with GluR1-re-
lated synaptic potentiation (Hayashi et al., 2000). Pep1-TGL has
no effect on the basal AMPA receptor-mediated EPSCs (Toyoda
et al., 2007). However, the facilitatory effects of SKF81297 on
LTP were diminished by intracellular application of Pep1-TGL
(Figure 3D), suggesting that incorporation of homomeric GluR1
receptors plays a critical role in the facilitation of LTP by D1
receptor activation.
We also measured the effects of SKF81297 on NMDA recep-
tor-mediated responses and found that bath application of
SKF81297 did not affect NMDA EPSCs (Figure 3E). Therefore,
the facilitation of LTP by D1 receptor activation is not likely due
to its direct modulation of NMDA receptors. In addition, there
was no difference in the expression levels of D1 receptors in
PFC slices between WT andFmr1/mice (Figure 3F), and the af-
finity of D1 receptor agonist was not changed in PFC of Fmr1/mice (Figure 3G). Thus, the impairment of DA-induced facilitation
of synaptic potentiation is not due to a defect in D1 receptors.
Impaired D1 Receptor Signaling in PFC of Fmr1/Mice
D1 receptors preferentially couple to Gs proteins, stimulating the
activity of adenylyl cyclases (ACs) and PKA pathways (Huang
and Kandel, 1995; Missale et al., 1998). We determined the effect
of the D1 receptor agonist SKF81297 on ACs with a cAMP assay
and found that the increase in cAMP caused by SKF81297 was
attenuated in both PFC neuronal cultures and slices from Fmr1/
mice (p < 0.01, n = 6; Figures 4A and 4B). However, there was
no difference in cAMP increase caused by the AC activator for-
skolin between Fmr1/ and WT mice (Figures 4A and 4B). These
data indicate that the coupling between D1 receptors and ACs is
impaired, whereas the activity of ACs is not affected in PFC of
Fmr1/ mice. To address whether D1 receptor coupling is spe-
cifically affected in Fmr1/ mice, we investigated the effect of
AS19, a selective 5-HT7 receptor agonist (Perez-Garcia and
Meneses, 2005), in cultured PFC neurons and PFC slices from
Fmr1/ mice. We found that the cAMP increase caused
by AS19 in Fmr1/ mice was similar to that of WT mice
(Figures S5A and S5B). These findings indicate that the 5-HT7
receptor-cAMP pathway is normal and that the D1 receptorNeuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 637
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way Is Impaired in PFC of Fmr1/ Mice
(A and B) cAMP assay in PFC neuronal culture (A)
and slices (B). The cAMP increase after SKF81297
was impaired in Fmr1/ mice compared to WT.
There was no difference in cAMP levels after for-
skolin treatment between Fmr1/ and WT mice.
Cultured cortical neurons or slices were treated
with 10 mM and 50 mM forskolin or 5 mM and
25 mM SKF81297 for 10 min. n = 6 wells in (A),
n = 6 mice in (B) per group.
(C) Basal Gas protein levels were not changed in
PFC slices from Fmr1/ mice as shown by west-
ern blot. n = 4 mice per group.
(D) The G protein activators GTP-g-S and NaF in-
creased cAMP levels in PFC slices. There was no
difference between Fmr1/ and WT mice. n = 6
mice per group.
(E) D1 receptor-Gs protein coupling is impaired in
PFC of Fmr1/ mice. D1 receptor-Gs protein cou-
pling increased in PFC slices after treatment with
the D1 receptor agonist SKF81297 (5 mM) for 10
min as shown by coimmunoprecipitation (CoIP).
Homogenate of PFC slices was immunoprecipi-
tated with Gas antibody. n = 4 mice per group.
(F) Similar results were obtained when homoge-
nate of PFC slices was immunoprecipitated with
D1 receptor antibody.
(G) D1 receptor phosphorylation at serine (Ser)
sites was increased in PFC of Fmr1/ mice as
shown by CoIP. D1 receptor phosphorylation at
tyrosine (Tyr) sites was not changed in PFC of
Fmr1/ mice. n = 4 mice per group.
(H) Total expression levels of GRK2 and GRK4–6
were not affected in Fmr1/ mice as shown by
western blot. n = 4 mice per group.
(I) Expression levels of GRK2 were increased while
GRK4–6 was unchanged in membrane prepara-
tion from PFC of Fmr1/ mice versus WT. n = 4
mice per group.
(J) Expression levels of GRK2 were decreased
while GRK4–6 was unchanged in cytosol prepara-
tion from PFC of Fmr1/ mice versus WT. n = 4
mice per group.
Data are normalized to WT values in (C) and (G)–(J)
or to WT control values in (E) and (F) and are
expressed as mean ± SEM. *p < 0.05, **p < 0.01
versus control; #p < 0.01 versus WT in (A)–(F).
**p < 0.01 versus WT in (G)–(J).signaling pathway is selectively affected in the PFC of Fmr1/
mice. We then checked the expression and function of Gas pro-
tein in Fmr1/mice and found no difference in the basal levels of
Gas protein in the PFC between Fmr1
/ and WT mice
(Figure 4C). In addition, the increase in cAMP level caused by
the G protein activators GTP-g-S or NaF was not affected in
PFC slices of Fmr1/ mice compared to WT mice (Figure 4D).
These results indicate that the expression and function of Gas
protein are not affected in PFC of Fmr1/ mice.
We next investigated the coupling of D1 receptors to Gas by
coimmunoprecipitation (Jones et al., 2000). We found that cou-
pling of D1 receptors to Gs protein remained unchanged under
basal conditions in PFC slices of Fmr1/ mice (Figures 4E and
4F). In contrast, the D1 receptor agonist SKF81297 increased638 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.the coupling of D1 receptors to Gas protein in PFC slices of
WT mice. Interestingly, the increase induced by SKF81297 was
attenuated in Fmr1/ mice (p < 0.01 versus WT, n = 4 mice; Fig-
ures 4E and 4F), indicating that coupling of D1 receptors to Gas
protein due to D1 receptor activation is impaired in PFC of
Fmr1/ mice. D1 receptor phosphorylation modulates its inter-
action with Gs proteins (Gainetdinov et al., 2004; Missale et al.,
1998). Here, we found that D1 receptor phosphorylation at serine
sites was increased in PFC of Fmr1/ mice relative to WT mice
(185.0% ± 15.3% of WT; p < 0.01, n = 4 mice; Figure 4G),
whereas the phosphorylation at tyrosine sites was not changed
(Figure 4G). These data reveal that D1 receptors are hyperphos-
phorylated in PFC of Fmr1/ mice, which might account for the
impaired coupling of D1 receptors to Gs protein in Fmr1
/ mice.
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(A) CoIP of FMRP and GRK2 in PFC homogenate. GRK2 immunoreactivity was
observed in FMRP immunoprecipitates (top panel) and FMRP immunoreactiv-
ity was observed in GRK2 immunoprecipitates (bottom panel), whereas neither
GRK2 nor FMRP immunoreactivity was present in control IgG immunoprecip-
itates as shown by western blot (WB).
(B) No immunoreactivity for GRK4–6, D1 receptors, Gas, GluR1, or 5-HT7 re-
ceptor was observed in FMRP immunoprecipitates.
(C) No FMRP immunoreactivity was detected in input of PFC homogenate from
Fmr1/ mice; neither FMRP nor GRK2 was observed in immunoprecipitates
with FMRP antibody in Fmr1/ mice (top panel). No FMRP immunoreactivity
was observed in immunoprecipitates with GRK2 antibody from PFC homoge-
nate of Fmr1/ mice (bottom panel).
(D) GRK2, but not FMRP, was detected in input of the membrane (Mem) prep-
aration from PFC; neither FMRP nor GRK2 was observed in immunoprecipi-
tates with FMRP antibody in membrane preparation (top panel). Both GRK2
and FMRP were detected in input of the cytosol (Cyt) preparation from PFC;
both FMRP and GRK2 were observed in immunoprecipitates with FMRP anti-
body in cytosol preparation (bottom panel).
(E) Colocalization of FMRP and GRK2 in both neuronal soma and dendrites of
cultured PFC neurons. FMRP and GRK2 were labeled with FITC or rhodamine-
conjugated secondary antibody, respectively. Immunofluorescence stainingGRKs phosphorylate GPCRs and modulate the efficacy of
GPCR signaling pathways (Gainetdinov et al., 2004; Premont
and Gainetdinov, 2007). Previous studies have shown that DA re-
ceptors can be phosphorylated by GRKs (Gainetdinov et al.,
2004; Premont and Gainetdinov, 2007). We investigated the ex-
pression of GRKs in PFC and found that the total expression
levels of GRK2 and GRK4–6 were not changed in PFC of
Fmr1/ mice compared to WT mice (Figure 4H). Interestingly,
the level of GRK2 in cell membrane preparation was increased,
whereas it was decreased in cytosol preparation from PFC of
Fmr1/ mice compared to WT mice (p < 0.01, n = 4 mice; Fig-
ures 4I and 4J). However, the levels of GRK4–6 in both mem-
brane and cytosol preparations were not changed (Figures 4I
and 4J). These results suggest that D1 receptor hyperphosphor-
ylation might be caused by subcellular redistribution of GRK2 in
PFC neurons of Fmr1/ mice and that GRK2 may be a key iso-
form of GRKs responsible for the impaired D1 receptor signaling
in Fmr1/ mice.
FMRP Interacts with GRK2
FMRP interacts physically with other proteins (Hayashi et al.,
2007; Menon et al., 2004), and GRKs have been shown to inter-
act with other nonreceptor proteins (Ribas et al., 2007). We found
that FMRP and GRK2 could interact with each other (Figure 5A).
In contrast, FMRP did not interact with GRK4–6, D1 receptors,
Gas, GluR1, or 5-HT7 receptors (Figure 5B). The interaction be-
tween FMRP and GRK2 was not due to nonspecific binding of
antibodies, as shown in Figure 5C. FMRP was not present in
the cell membrane, and the interaction between FMRP and
GRK2 was only detected in the cytosol preparation of PFC
(Figure 5D). Furthermore, we found that FMRP and GRK2 were
colocalized in both the soma and dendrites of cultured PFC neu-
rons (Figure 5E). These findings demonstrate that endogenous
FMRP and GRK2 interact, suggesting that FMRP may regulate
subcellular distribution of GRK2 through protein-protein interac-
tions and that lack of FMRP leads to redistribution of GRK2 in
PFC neurons of Fmr1/ mice.
D1 Receptor Signaling in Striatum of Fmr1/ Mice
To address whether D1 receptor signaling is specifically affected
in PFC of Fmr1/ mice, we evaluated D1 receptor signaling in
striatum, a key brain region receiving dopaminergic input (Cen-
tonze et al., 2003; Hallett et al., 2006; West and Grace, 2002).
We compared the effect of the D1 receptor agonist SKF81297
on ACs in the striatum between WT and Fmr1/ mice and found
that the increase of cAMP was attenuated in striatal slices of
Fmr1/ mice (p < 0.01, n = 4 mice; Figure 6A). However, there
was no difference in the cAMP increase caused by the AC acti-
vator forskolin or the 5-HT7 receptor agonist AS19 between
Fmr1/ and WT mice (Figures 6A and 6B). These results sug-
gest that the coupling between D1 receptors and ACs is also af-
fected in striatum of Fmr1/ mice. There was no difference in
the basal levels of Gas protein in striatum of Fmr1
/ and WT
mice (Figure 6C). The D1 receptor agonist SKF81297 increased
for FMRP (top), GRK2 (middle), and merged FMRP/GRK2 (bottom) is shown.
Scale bars = 20 mm.Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 639
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way in Striatum of Fmr1/ Mice
(A) cAMP assay in striatum slices. The cAMP in-
crease after treatment with the D1 receptor ago-
nist SKF81297 was impaired in Fmr1/ mice
compared with WT mice. There was no difference
in cAMP levels after forskolin treatment between
Fmr1/ and WT mice. Striatal slices were treated
with 10 mM and 50 mM forskolin or 5 mM and 25 mM
SKF81297 for 10 min. n = 4 mice per group.
(B) cAMP increase after treatment with the 5-HT7
receptor agonist AS19 (10 nM and 100 nM for
15 min) was not changed in striatal slices of
Fmr1/ mice. n = 4 mice per group.
(C) Basal Gas protein levels were not changed in
striatal slices from Fmr1/ mice versus WT mice
as shown by western blot. n = 4 mice per group.
(D) D1 receptor-Gs protein coupling is impaired in
striatum of Fmr1/ mice. The coupling of D1 re-
ceptor-Gas increased in striatal slices after treat-
ment with the D1 receptor agonist SKF81297
(5 mM) for 10 min as shown by CoIP. The homo-
genate was immunoprecipitated with Gas anti-
body. n = 4 mice per group.
(E) D1 receptor phosphorylation at serine sites was
increased in striatum of Fmr1/ mice as shown by
CoIP. n = 4 mice per group.
(F) D1 receptor phosphorylation at tyrosine sites
was not changed in striatum of Fmr1/ mice as
shown by CoIP. n = 4 mice per group.
(G) Expression levels of GRK2 were increased in
membrane preparation from striatum of Fmr1/
mice compared to WT mice. n = 4 mice per group.
(H) Expression levels of GRK2 were decreased in
cytosol preparation from striatum of Fmr1/
mice compared to WT mice. n = 4 mice per group.
(I) CoIP of FMRP and GRK2 in striatal homoge-
nate. GRK2 immunoreactivity was observed in
FMRP immunoprecipitates; no GRK2 immunore-
activity was present in control IgG immunoprecip-
itates.
Data are normalized to WT values in (C) and (E)–(H)
or to WT control values in (D) and are expressed as
mean ± SEM. *p < 0.05, **p < 0.01 versus control;
#p < 0.01 versus WT in (A), (B), and (D). **p < 0.01
versus WT in (E), (G), and (H).coupling of D1 receptors to Gas protein in striatal slices of WT
mice, whereas this increase was attenuated in Fmr1/ mice
(p < 0.01 versus WT, n = 4 mice; Figure 6D). D1 receptors were
hyperphosphorylated at serine sites (192% ± 13% of WT; p <
0.01, n = 4 mice; Figure 6E), whereas phosphorylation at tyrosine
sites was unchanged in striatum of Fmr1/ mice (Figure 6F).
Furthermore, we found that GRK2 was increased in membrane
and decreased in cytosol preparations from striatum of Fmr1/
mice (p < 0.01, n = 4 mice; Figures 6G and 6H). Finally, FMRP
interacted with GRK2 in striatum (Figure 6I). These data point
to an impairment of D1 receptor signaling in Fmr1/ striatum.
Rescue of D1 Receptor Signaling in Fmr1/ Neurons
by Expressing FMRP
If the impaired D1 receptor signaling is due to the lack of FMRP,
we expect that the expression of FMRP in Fmr1/ neurons
should rescue this deficit. Transfection of FMRP constructs640 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.into cultured Fmr1/ PFC neurons (Figure 7A) resulted in in-
creased membrane and decreased cytosolic expression of
GRK2 (Figure 7B). The redistribution of GRK2 between mem-
brane and cytosol was reversed by FMRP expression in
Fmr1/ PFC neurons (Figures 7C and 7D). Consistently, expres-
sion of FMRP in Fmr1/ neurons reduced the increased D1
receptor phosphorylation at serine sites to a level similar to
WT neurons (Figures 7E and 7F). In addition, FMRP expression
reversed deficits in both coupling of D1 receptors to Gas
and cAMP production caused by the D1 receptor agonist
SKF81297 in Fmr1/ PFC neurons (Figures 7G–7I). Application
of SKF81297 caused a similar increase of GluR1 phosphoryla-
tion (Ser845) in WT and Fmr1/ PFC neuronal culture with
FMRP expression (Figure 7J), with no difference in GluR1 surface
expression (Figure 7K). These data demonstrate that FMRP ex-
pression rescues the alterations in D1 receptor signaling and
its downstream effect on AMPA receptors in Fmr1/ neurons.
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Receptor Signaling Pathway in PFC Neu-
rons of Fmr1/ Mice
Cultured PFC neurons at 16 days in vitro (DIV16)
were transfected with FMRP expression vectors
or empty plasmid vector as control.
(A) FMRP expression was detected by western
blot 2 days after transfection.
(B) GRK2 expression levels were increased in
membrane preparation and decreased in cytosol
preparation from cultured PFC neurons of
Fmr1/ mice versus WT mice. n = 4 dishes per
group.
(C) FMRP expression reduced the increased
GRK2 levels in membrane preparation of Fmr1/
mice. GRK2 levels were similar to WT culture
transfected with control vector. n = 4 dishes per
group.
(D) FMRP expression increased the decreased
GRK2 levels in cytosol preparation from Fmr1/
cultured PFC neurons. GRK2 levels were similar
to that in WT culture transfected with control vec-
tor. n = 4 dishes per group.
(E) D1 receptor phosphorylation at serine sites
was increased in cultured PFC neurons of
Fmr1/ mice as shown by CoIP and western
blot. n = 4 dishes per group.
(F) FMRP expression reduced the increased D1 re-
ceptor phosphorylation at serine sites in Fmr1/
cultured PFC neurons. D1 receptor phosphoryla-
tion at serine sites was similar to that in WT culture
transfected with control vector. n = 4 dishes per
group.
(G) D1 receptor-Gs protein coupling is impaired in
cultured PFC neurons of Fmr1/ mice. The cou-
pling of D1 receptor-Gas increased in PFC slices
after treatment with the D1 receptor agonist
SKF81297 (5 mM, 10 min) in WT neurons, and the
increase in coupling was attenuated in Fmr1/
culture, as shown by CoIP and western blot. Ho-
mogenate of PFC slices was immunoprecipitated
with D1 receptor antibody. n = 4 dishes per group.
(H) FMRP expression increased the decreased D1
receptor-Gs protein coupling in cultured PFC neu-
rons of Fmr1/ mice. D1 receptor-Gs protein cou-
pling levels were similar to that in WT culture trans-
fected with control vector. n = 4 dishes per group.
(I) FMRP expression increased the attenuated
cAMP production caused by SKF81297 (5 mM,
10 min) in cultured PFC neurons of Fmr1/
mice. The cAMP levels in Fmr1/ culture with
FMRP expression were similar to that in WT cul-
ture transfected with control vector. n = 5 wells
per group.
(J) FMRP expression increased GluR1 phosphorylation (Ser845) caused by SKF81297 (5 mM, 10 min) in cultured PFC neurons of Fmr1/ mice. GluR1 phosphor-
ylation (Ser845) levels after SKF81297 treatment were similar to that in WT culture transfected with control vector. n = 4 dishes per group.
(K) FMRP expression increased the attenuated GluR1 surface expression caused by SKF81297 (5 mM, 10 min) in cultured PFC neurons of Fmr1/ mice. GluR1
surface expression levels were similar to that in WT culture transfected with control vector. n = 4 dishes per group.
Western blot data were normalized to WT control values in (C), (D), (F)–(H), (J), and (K) or to WT values in (B) and (E) and are expressed as mean ± SEM. **p < 0.01
versus WT in (B)–(F). #p < 0.01 versus WT in (G) and (I) or versus Fmr1/ control in (C), (D), and (F). *p < 0.05, **p < 0.01 versus control in (G)–(K).Pharmacological Rescue of D1 Receptor Signaling
in Fmr1/ Neurons
To see whether it is possible to rescue D1 receptor signaling by
inhibiting GRK2 in Fmr1/ neurons, we tested the nonspecific
GRK inhibitor heparin (Fraga et al., 2004; Freedman et al., 2002)and a GRK2 peptide inhibitor (Winstel et al., 2005). Neither hepa-
rin nor the GRK2 peptide inhibitor affected D1 receptor phos-
phorylation at serine or tyrosine sites in cultured WT PFC neurons
(Figures 8A and 8B). However, both heparin and the GRK2 pep-
tide inhibitor could reduce D1 receptor hyperphosphorylationNeuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 641
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GRK2 Rescues the D1 Receptor Signaling
Pathway in PFC Neurons of Fmr1/ Mice
The GRK inhibitor heparin (10 mM) and GRK2 pep-
tide inhibitor (2 mM) were applied to cultured PFC
neurons at DIV16 in the presence of lipofectin
(5 mg/ml). Experiments were carried out after 6 hr
treatment with heparin or GRK2 peptide inhibitor.
(A) Heparin and GRK2 peptide inhibitor (GRK2 PI)
did not affect basal D1 receptor phosphorylation
at serine sites in cultured PFC neurons as shown
by CoIP and western blot. n = 3 dishes per group.
(B) Heparin and GRK2 peptide inhibitor did not af-
fect basal D1 receptor phosphorylation at tyrosine
sites in cultured PFC neurons as shown by CoIP
and western blot. n = 3 dishes per group.
(C) Basal D1 receptor phosphorylation at serine
sites was increased in cultured PFC neurons of
Fmr1/ mice compared to WT mice; the increase
was blocked by heparin or GRK2 peptide inhibitor
as shown by CoIP and western blot. n = 4 dishes
per group. **p < 0.01 versus WT; ##p < 0.01 versus
Fmr1/ control.
(D) After application of heparin or GRK2 peptide in-
hibitor in Fmr1/ culture, the increase in coupling
of D1 receptor-Gas caused by the D1 receptor ag-
onist SKF81297 (5 mM, 10 min) was similar to that
in WT culture. n = 4 dishes per group; **p < 0.01
versus control.
(E) Heparin or GRK2 peptide inhibitor did not affect
basal cAMP levels or the increase of cAMP pro-
duction caused by SKF81297 (5 mM, 10 min) in
WT culture as shown by cAMP assay. n = 5 wells
per group; **p < 0.01 versus control.
(F) After application of heparin or GRK2 peptide in-
hibitor, the D1 receptor agonist SKF81297 (5 mm,
10 min) could cause a further increase in cAMP
levels in Fmr1/ culture; the cAMP levels were
similar to those in WT culture. n = 5 wells per
group. *p < 0.05, **p < 0.01 versus control;
#p < 0.01 versus WT.
(G) Heparin or GRK2 peptide inhibitor did not af-
fect the increase of GluR1 phosphorylation
(Ser845) or GluR1 surface expression caused by
SKF81297 (5 mM, 10 min) in WT culture as shown
by western blot and biotinylation assay. n = 4
dishes per group; **p < 0.01 versus control.
(H) After application of heparin or GRK2 peptide
inhibitor in Fmr1/ culture, there was no
difference in the increase of GluR1 phosphorylation (Ser845) caused by SKF81297 (5 mM, 10 min) between Fmr1/ and WT culture as shown by western
blot. n = 4 dishes per group; **p < 0.01 versus control.
(I) No difference was found in the increase of GluR1 surface expression caused by SKF81297 (5 mM, 10 min) between Fmr1/ and WT culture as shown by
biotinylation assay. n = 4 dishes per group; **p < 0.01 versus control.
Western blot data were normalized to WT control values in (C), (D), (H), and (I) or to control values in (A), (B), and (G) and are expressed as mean ± SEM.at serine sites in Fmr1/ neurons to levels similar to that of WT
(Figure 8C). Furthermore, both heparin and the GRK2 peptide in-
hibitor could reverse deficits in coupling of D1 receptors to Gas
and cAMP production stimulated by the D1 receptor agonist
SKF81297 inFmr1/PFC neurons (Figures 8D and 8F), although
cAMP production in WT PFC culture was unaffected (Figure 8E).
We also found that heparin and the GRK2 peptide inhibitor did not
affect GluR1 phosphorylation (Ser845) or surface expression
caused by SKF81297 in WT PFC neuronal culture (n = 4 dishes;
Figure 8E). However, they could reverse the deficits in GluR1642 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.phosphorylation (Ser845) and GluR1 surface expression induced
by SKF81297 in Fmr1/ neurons (Figures 8H and 8I). These re-
sults show that pharmacological inhibition of GRK2 can rescue
D1 receptor signaling and its downstream effect on AMPA recep-
tors in Fmr1/ neurons.
Another way to rescue D1 receptor signaling in Fmr1/ neu-
rons is to directly activate ACs, bypassing D1 receptors. In
PFC slices of WT mice, we found that coapplication of forskolin,
an AC activator, with the D1 receptor agonist SKF81297 could
cause further increase of cAMP compared to SKF81297 alone
Neuron
FMRP and Dopamine Modulation in ForebrainFigure 9. Effect of D1 Receptor Activation on Behavior in Fmr1/
Mice
(A) Sample traces of locomotor activity in the open-field test for control- and
SKF81297-injected WT or Fmr1/ mice, respectively.
(B and C) Fmr1/ mice traveled more than WT mice at basal condition (n = 8
mice for WT, n = 7 mice for Fmr1/; p < 0.05). The D1 agonist SKF81297
(1 mg/kg body weight, injected intraperitoneally) significantly reduced the
distance traveled by Fmr1/ mice (n = 7 mice for control, n = 8 mice
for SKF81297; p < 0.05), whereas it did not affect locomotor activity in WT
mice (n = 8 mice; p > 0.05).
(D and E) SKF81297 did not affect the percentage of time spent by Fmr1/
(n = 7 mice for control, n = 8 mice for SKF81297; p > 0.05) or WT (n = 8 mice
for both control and SKF81297; p > 0.05) mice in the open arms (D) or the
total number of arm entries (E) in the elevated plus-maze test.
(F) Application of the D1 receptor agonist SKF81297 (1 mg/kg body weight, in-
jected intraperitoneally) did not affect the performance of WT mice (n = 6 mice(p < 0.05, n = 4 mice; Figure S6A), indicating that ACs can be
further activated by forskolin in the presence of D1 receptor
agonist. In Fmr1/ PFC slices, coapplication of forskolin
and SKF81297 could further increase cAMP compared to
SKF81297 alone (p < 0.01, n = 4 mice; Figure S6B). The increase
of cAMP caused by coapplication of forskolin and SKF81297 in
PFC slices of Fmr1/ mice was similar to that caused by
SKF81297 alone in WT PFC slices (p > 0.05, n = 4 mice;
Figure S6B). GluR1 phosphorylation (Ser845) and GluR1 surface
expression induced by SKF81297 were impaired in Fmr1/ PFC
slices compared to WT (p < 0.01, n = 4 mice; Figures S6C and
S6D). However, when SKF81297 was coapplied with forskolin
in Fmr1/ PFC slices, the increases of GluR1 phosphorylation
(Ser845) and GluR1 surface expression were similar to those
caused by SKF81297 alone in WT (p > 0.05, n = 4 mice; Figures
S6C and S6D). Thus, D1 receptor signaling and its downstream
effect on AMPA receptors can be rescued by stimulating ACs in
Fmr1/ neurons.
The Effect of DA D1 Receptor Activation
on Behavior of Fmr1/ Mice
Fragile X patients and animal models exhibit behavioral pheno-
types that are consistent with deficits in PFC function, such as
hyperactivity, anxiety, and learning abnormalities (Bear et al.,
2004; Moon et al., 2006; Ventura et al., 2004). We analyzed loco-
motor activity in the open-field test to characterize hyperactivity,
a common phenotype in fragile X syndrome. We found increased
locomotor activity in Fmr1/ mice (p < 0.05, n = 8 mice for WT,
n = 7 mice for Fmr1/; Figures 9A–9C), and application of the D1
receptor agonist SKF81297 reduced this hyperactivity (p < 0.05,
n = 7 mice for control, n = 8 mice for SKF81297; Figures 9D and
9E). The locomotor activity in WT mice remained unaffected fol-
lowing SKF81297 injection (Figures 9A–9C). These data indicate
that Fmr1/ mice exhibit hyperactivity and that excessive D1
receptor agonist can partially rescue this phenotype. We then
investigated anxiety-like behaviors with the elevated plus-maze
test. We found no differences between Fmr1/ and WT mice
and no effect of SKF81297 (Figures 9D and 9E). These data
indicate that anxiety-like behaviors are not detectable in this
fragile X mouse model and suggest that these behaviors are
probably not related to the D1 receptor signaling pathway.
The striatum is involved in motor coordination and skill learning
(Calabresi et al., 2007; Centonze et al., 2003; Schultz et al.,
2003). We investigated the motor function of the animals with
the rotarod test and found that the D1 receptor agonist
SKF81297, at a dose that did not affect the behavior of WT
mice, could enhance the performance of Fmr1/ mice (p <
0.05, n = 8 mice for control, n = 7 mice for SKF81297;
Figure 9F). These data suggest that D1 receptor signaling might
for control and SKF81297, respectively) but could enhance the performance of
Fmr1/ mice in the rotarod test (n = 8 mice for control, n = 7 mice for
SKF81297). The baseline performance of Fmr1/ mice in the rotarod test
was not significantly different compared to WT mice (n = 8 mice for Fmr1/,
n = 6 mice for WT; p > 0.05).
For all experiments, mice injected with sterile saline at the same volume as
SKF81297 were used for control. Data in (B)–(F) are expressed as mean ±
SEM. *p < 0.05 versus WT; #p < 0.05 versus control.Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 643
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tive to excessive D1 receptor agonist. However, under basal
conditions, there was no difference in motor function between
Fmr1/ and WT mice (Figure 9F), which might be explained
by the possible saturation of D1 receptor signaling.
DISCUSSION
We have provided strong evidence that FMRP acts as a key mes-
senger for DA-mediated modulation of excitatory transmission in
forebrain neurons. FMRP is required for surface expression of
AMPA GluR1 receptors in response to D1 receptor activation. Fa-
cilitation of LTP by D1 receptor activation was consistently absent
in the cingulate region of PFC of Fmr1/ mice. Previously, we re-
ported that FMRP is required for NMDA receptor-dependent LTP
in the cingulate region of PFC (Zhao et al., 2005a). Together, our
findings indicate that FMRP acts as a key messenger in both
NMDA receptor-dependent LTP and DA receptor-mediated facil-
itation. FMRP is involved in DA signaling through its interaction
with GRK2. Expressing FMRP in Fmr1/ neurons or inhibition
of GRK2 rescued D1 receptor signaling in PFC. In addition, D1
receptor agonist partially rescued hyperactivity and enhanced
motor function in Fmr1/ mice. These data indicate that FMRP
acts as a messenger for the DA system in the forebrain.
FMRP, DA Modulation of AMPA Receptors,
and Synaptic Potentiation
D1 receptor activation has been reported to increase AMPA re-
ceptor surface expression and to facilitate AMPA receptors’ syn-
aptic insertion (Gao et al., 2006; Smith et al., 2005; Sun et al.,
2005). Here, we further compared the effects of D1 receptor ac-
tivation on GluR1 surface expression in cultured PFC neurons to
illustrate the role of FMRP in dopaminergic modulation of GluR1
receptors. We found that D1 receptor activation can increase
GluR1 surface expression in PFC neurons, but this increase
was significantly attenuated in Fmr1/ neurons. We also found
that D1 receptor activation could induce GluR1 phosphorylation
at the PKA phosphorylation site and that this induction was al-
most blocked in Fmr1/ PFC neurons. These results indicate
that FMRP is involved in the regulation of GluR1 receptors by
D1 receptors through the PKA signaling pathway.
Synapses in cingulate cortex undergo plasticity and are
involved in higher brain functions such as learning and memory,
drug addiction, and pain (Courtney et al., 1998; Frankland et al.,
2004; Zhao et al., 2005b; Zhuo, 2002, 2008). The DA system
modulates LTP and long-term depression (LTD) in PFC (Huang
et al., 2004; Seamans and Yang, 2004), and we found that D1 re-
ceptor activation facilitated cingulate prefrontal LTP through in-
creased synaptic incorporation of homomeric GluR1. Unaltered
PPF suggests that facilitation of LTP by D1 receptor activation in
the cingulate PFC likely depends on a postsynaptic mechanism.
However, we cannot rule out possible presynaptic modulation of
inhibitory transmission (Kandel, 2001; Nicola and Malenka,
1997), which was blocked in our recordings. Notably, D1 recep-
tor activation facilitated LTP in WT mice but not in Fmr1/ mice,
suggesting that GluR1 insertion induced by dopaminergic acti-
vation is impaired. These data reveal deficits in DA modulation
of synaptic plasticity in Fmr1/ mice.644 Neuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc.FMRP and D1 Receptor Signaling
D1 receptors are positively coupled to ACs through Gs proteins
(Huang et al., 2004; Jaber et al., 1996; Missale et al., 1998). We
found that the coupling of D1 receptors to Gs protein by D1 re-
ceptor activation is impaired in PFC of Fmr1/ mice. D1 recep-
tor phosphorylation modulates interaction with Gs proteins
(Gainetdinov et al., 2004; Ribas et al., 2007). We found that D1
receptor phosphorylation at serine sites was increased in PFC
of Fmr1/ mice, which might account for the impaired coupling
of D1 receptors to Gs protein. DA D1 receptors can be phosphor-
ylated by GRKs (Gainetdinov et al., 2004; Ribas et al., 2007). We
found that GRK2 levels were increased in the cell membrane but
decreased in the cytosol in PFC of Fmr1/ mice. These results
suggest that D1 receptor hyperphosphorylation might be caused
by the subcellular redistribution of GRK2 in PFC of Fmr1/ mice
and that FMRP might modulate the subcellular distribution of
GRK2. Furthermore, FMRP interacts with GRK2, suggesting
that FMRP may regulate subcellular distribution of GRK2 and
D1 receptor signaling through a direct interaction. Notably, D1
receptor signaling is also impaired in striatum of Fmr1/ mice,
supporting the idea that FMRP acts as a common messenger
for DA modulation in different brain areas.
Reversal of Impaired D1 Receptor Signaling
in Fmr1/ Neurons
We have demonstrated that FMRP expression can rescue D1 re-
ceptor signaling in Fmr1/ neurons, providing further evidence
for a link between FMRP and D1 receptor signaling. We found
that GRK2 inhibitors could reverse D1 receptor signaling and
its downstream effect on AMPA GluR1 receptors. Additionally,
the function of ACs is not affected in Fmr1/ neurons, and di-
rectly stimulating ACs by forskolin could also rescue D1 receptor
signaling in Fmr1/ neurons, providing another option for regu-
lating D1 receptor signaling in Fmr1/ neurons.
D1 Receptor Agonist-Improved Behavioral
Phenotype of Fmr1/ Mice
The behavioral phenotypes of fragile X syndrome consist of
hyperactivity, anxiety, autism, and cognitive deficits (Bear
et al., 2004; Moon et al., 2006; Ventura et al., 2004). Here, we
found increased locomotor activity in Fmr1/ mice that could
be reduced by D1 receptor agonist treatment. These data indi-
cate that Fmr1/ mice are hyperactive and suggest this might
be caused by defects in D1 receptor signaling. Since D1 receptor
agonists typically activate locomotor activity (Heijtz et al., 2007),
it is interesting that SKF81297 reduced hyperactivity in Fmr1/
mice. However, this is consistent with the paradoxical ability of
stimulants to alleviate hyperactivity in attention deficit hyperac-
tivity disorder (ADHD), which is prevalent in fragile X patients
(Arnsten, 2006; Sullivan et al., 2006). Previously, amphetamine
injection, which increases dopamine release, was shown to im-
prove cognitive function in Fmr1/ mice (Ventura et al., 2004).
Taken together, these findings indicate that the dysfunction of
the DA system could be an underlying mechanism for the behav-
ioral phenotypes of fragile X syndrome.
In summary, we have shown that FMRP plays a key role in
DA modulation of synaptic plasticity and DA-related behav-
iors. FMRP modulates D1 receptor signaling by regulating the
Neuron
FMRP and Dopamine Modulation in Forebrainsubcellular distribution of GRK2. Our study has identified FMRP
as a key messenger for DA modulation, at least in the forebrain,
and may provide insights into the cellular mechanisms underly-
ing fragile X syndrome.
EXPERIMENTAL PROCEDURES
Animals
Fmr1 WT and Fmr1/ mice (male, 6–8 weeks of age) of the FVB.129P2-
Fmr1tm1Cgr strain were used and maintained as described previously (Weiler
et al., 2004; Zhao et al., 2005a). The Animal Care and Use Committee of
University of Toronto approved all mouse protocols.
Primary Neuronal Culture
PFC neurons were prepared from postnatal day 0 (P0) using methods as de-
scribed previously (Wang et al., 2007). Cultures were used for experiments be-
tween 16 and 18 days in vitro (DIV). Cytosolic and membrane extracts were
prepared from PFC slices or cultures of WT and Fmr1/ mice as described
previously (Morozov et al., 2003).
Transfection and Application of GRK2 Inhibitor in Neuronal Cultures
Cultured PFC neurons at DIV16 were transfected with FMRP expression
vector or an empty vector (control) after reconstitution with NeuroPORTER
transfection reagent (Sigma). Experiments were carried out on day 2 after
transfection. The nonspecific GRK inhibitor heparin (10 mM) and GRK2 peptide
inhibitor (2 mM) were applied to cultured PFC neurons at DIV16 in the presence
of lipofectin (5 mg/ml) to facilitate their entry into cells. Assays were carried out
after 6 hr of treatment.
Immunoprecipitation
For detection of D1 receptor phosphorylation, solubilized protein samples were
prepared with modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF) and precipi-
tated with 50ml of protein G-agarose precoupled with anti-D1 receptor antibody
for 4 hr at 4C. The reaction mixtures were then washed three times, eluted by
boiling in loading buffer, and subjected to western blot using antibodies to anti-
phosphoserine or anti-phosphotyrosine (BD Biosciences). For detection of pro-
tein-protein interactions by coimmunoprecipitation, protein samples from PFC
were precleared by incubation with protein G-agarose, and D1 receptors or
FMRP were precipitated with an anti-D1 receptor or anti-FMRP antibody, re-
spectively (Chemicon). Immunocomplexes were captured with protein A-aga-
rose for 4 hr, and pellets were washed four times and eluted by boiling in loading
buffer. Proteins were separated on 4%–12% SDS-PAGE gels and probed with
rabbit antibodies against Gas (Upstate), GRK2 (Santa Cruz), GRK4–6 (Upstate),
GluR1 (Chemicon), and 5-HT7 receptors (Chemicon). HRP-conjugated second-
ary antibodies and enhanced chemiluminescence were used to detect proteins.
Reaction mixtures without specific antibody were used for control.
Immunocytochemistry
Cultured PFC neurons were fixed at DIV18 with ice-cold 4% paraformaldehyde
in PBS (pH 7.4) for 30 min, blocked with 3% normal goat serum plus 3% BSA in
PBS for 2 hr, incubated with primary antibodies (FMRP antibody, 1:500; GRK2
antibody, 1:500) overnight, and then incubated with FITC-conjugated anti-
mouse IgG and rhodamine-conjugated goat anti-rabbit IgG (Chemicon) diluted
1:500 in blocking solution. Coverslips were mounted onto slides with VECTA
SHIELD mounting medium (Vector Laboratories). Staining was imaged and
analyzed using Image-Pro Plus (Media Cybernetics, Inc.).
Surface Biotinylation Assay
Surface GluR1 and GluR2/3 receptors were detected by a biotinylation assay,
followed by western blot analysis with GluR1 antibody (Upstate), anti-GluR2
and 3 (Chemicon), or pan-cadherin antibody (Sigma). At the end of
SKF81297 treatment, ice-cold PBS (with calcium and magnesium, pH 7.4;
Invitrogen) was added to prevent receptor internalization. After three washes
with ice-cold PBS, cells were incubated in sulfo-NHS-LC-biotin (0.3 mg/ml
in cold PBS; Pierce) for 30 min. Surface biotinylation was stopped by removalof the solution and incubation in 10 mM ice-cold glycine in PBS for 20 min.
Cells then were washed three times with cold PBS and lysed by RIPA buffer,
containing (in mM) 20 HEPES pH 7.4, 100 NaCl, 1 EGTA, 1 Na3VO4, 50 NaF,
1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, plus 1%
NP-40, 1% deoxycholate, 0.1% SDS, 10 mg/ml leupeptin, and 1 mg/ml aprotinin.
Biotinylated proteins were precipitated with 100 ml of ImmunoPure Immobi-
lized Streptavidin (Pierce), separated on 4%–12% SDS-PAGE gels, and trans-
ferred to polyvinylidene fluoride membranes. Membranes were probed with
anti-GluR1 antibody (1:3000), anti-GluR2 and 3 (1:3000), or anti-pan-cadherin
antibody (1:1000), followed by peroxidase-conjugated goat anti-rabbit anti-
body (1:3000; Sigma). Immunoreactive bands were visualized by ECL (Perki-
nElmer Life Sciences). The density of immunoblots was quantified by NIH
ImageJ software (http://rsbweb.nih.gov/ij/).
cAMP Assay
For cortical neuron culture, cells were plated in 24-well tissue culture dishes.
After treatment with forskolin (10 and 50 mM) or SKF81297 (5 and 25 mM) for
15 min, cells were harvested and lysed in 0.1 M HCl. Slices were incubated
with forskolin (10 and 50 mM) or SKF81297 (5 and 25 mM) in artificial cerebro-
spinal fluid (ACSF; in mM: 124 NaCl, 4.4 KCl, 2 CaCl2, 1 MgSO4, 25 NaHCO3,
1 NaH2PO4, 10 glucose) and lysed in 0.1 M HCl. To determine the G protein-
linked response of AC activity, samples were stimulated by 100 mM GTP-g-
S or 10 mM NaF. Phosphodiesterases were inhibited by the addition of 1
mM 3-isobutyl-1 methylxanthine (Sigma). Direct cAMP measurements were
performed using a direct cAMP enzyme immunoassay kit (Assay Designs)
according to the manufacturer’s protocol.
Dopamine Receptor Ligand Binding
PFC tissues from WT mice and Fmr1/ mice were resuspended in binding
buffer (50 mM Tris-HCl [pH 7.4], 5 mM EDTA, 1.5 mM CaCl2, 5 mM MgCl2,
5 mM KCl, 120 mM NaCl) and homogenized. For competition binding studies,
0.2 ml of membrane was incubated in duplicate with [3H]SCH23390 (275–350
pM) and increasing concentrations of SKF38393 (109 to 105 M) for 120 min.
Experiments were terminated by rapid filtration, and filters were monitored for
tritium. Nonspecific binding was defined in the presence of 10 mM (+)-butacla-
mol. Binding data were analyzed by the nonlinear least-square curve-fitting
program KaleidaGraph (Synergy Software). For all experiments, direct assay
comparisons between WT and Fmr1/ preparations were conducted on the
same day, using the same serial drug dilutions, and on the same batch of tis-
sue.
Electrophysiology
PFC brain slices (300 mm) were prepared using standard methods (Wang et al.,
2008; Wei et al., 2001). Slices were transferred to a submerged recovery cham-
ber containing oxygenated (95% O2/5% CO2) ACSF at room temperature for at
least 1 hr. Experiments were performed in a recording chamber on the stage of
an Axioskop 2 FS microscope with infrared DIC optics for visualizing whole-
cell patch-clamp recordings. EPSCs were recorded from layer II–III neurons
using an Axon 200B amplifier (Axon Instruments), and stimulations were deliv-
ered using a bipolar tungsten stimulating electrode placed in layer V of the pre-
frontal cortex, including the anterior cingulate cortex. EPSCs were induced by
repetitive stimulations at 0.02 Hz, and neurons were voltage clamped at 70
mV. The recording pipettes (3–5 MU) were filled with solution containing
(in mM) 145 K-gluconate, 5 NaCl, 1 MgCl2, 0.2 EGTA, 10 HEPES, 2 Mg-ATP,
and 0.1 Na3-GTP (adjusted to pH 7.2 with KOH). After obtaining stable EPSCs
for 10 min, three kinds of LTP induction paradigms were used within 12 min af-
ter establishing the whole-cell configuration to prevent washout effect on LTP
induction. The first protocol involved paired presynaptic 80 pulses at 2 Hz with
postsynaptic depolarization at +30 mV (referred to as pairing training). To test
neuronal excitability, current clamp was used. Spikes were evoked by injecting
depolarized current pulse (currents ranged from 100 to 150 pA to induce 3–4
spikes). To record the mEPSCs in culture neurons, 0.5 mM tetrodotoxin (TTX)
was added in the bath solution. Picrotoxin (100 mM) was always present to
block GABAA receptor-mediated inhibitory synaptic currents in slice record-
ings. To record NMDA receptor-mediated EPSCs, the AMPA receptor antag-
onist CNQX (20 mM) was also added, and holding potential was changed
to 20 mV to release Mg2+ blockade. The access resistance was 15–30 MUNeuron 59, 634–647, August 28, 2008 ª2008 Elsevier Inc. 645
Neuron
FMRP and Dopamine Modulation in Forebrainand was monitored throughout the experiment. Data were discarded if access
resistance changed by more than 15% during an experiment.
Behavioral Experiments
An Activity Monitor system (43.23 43.23 30.5 cm; Med Associates) was used
to record horizontal locomotor activity. Briefly, this system uses paired sets of
photo beams to detect movement in an open field, and movement is recorded
as beam breaks. The open field is placed inside a sound-attenuating chamber
with dim illumination and a fan. Forty-five minutes after intraperitoneal injection
of saline or SKF81297, each subject was placed in the center of the open field,
and activity was measured for 30 min. The elevated plus maze (Med Associ-
ates) consisted of two open arms and two closed arms situated opposite
each other, separated by a central platform. One hour after the open-field
test, animals were individually placed in the center square and allowed to
move freely for 5 min. Entries were defined as the mouse having all four paws
on an arm. The number of entries and time spent on each arm was recorded.
A video camera tracking system (EthoVision) was used to track the animals.
The animals’ motor functions were tested using the rotarod test. One hour
before testing, animals were trained on a rotarod (Med Associates) at a constant
velocity of 16 rpm until they could remain on for a 30 s period. The rotarod test
was performed by measuring the time each animal was able to maintain its bal-
ance walking on the rotating drum. The rotarod accelerated from 4 to 40 rpm
over a 5 min period. Mice were given three trials with a maximum time of 300 s
and a 5 min intertrial rest interval. The latency to fall was taken as a measure
of motor function. Some mice held on to the rotating drum instead of walking.
For these mice, the latency to fall was recorded after two complete rotations.
Data Analysis
Results are expressed as mean ± SEM. For electrophysiology, statistical com-
parisons were performed using one- or two-way analysis of variance (ANOVA)
using the Student-Newman-Keuls test for post hoc comparisons. For bio-
chemistry data, unpaired or paired t tests were used for comparisons. In all
cases, p < 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found online at http://www.
neuron.org/cgi/content/full/59/4/634/DC1/.
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